Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production
Relacorilant联合Pembrolizumab：一项针对伴有糖皮质激素分泌过多的肾上腺皮质癌患者的1b期开放标签研究，该研究评估了选择性糖皮质激素受体调节剂联合免疫检查点抑制剂的疗效。
期刊:Cold Spring Harbor Perspectives in Medicine
影响因子:10.1
doi:10.1101/cshperspect.a034892
Chakraborty, Rikhia; Abdel-Wahab, Omar; Durham, Benjamin H; Peters, S; Tabernero, J; Cervantes, A; Banerjee, S; Giuliani, R; Lordick, F; Silva Moreira, Ana Rita; Lagasse, Alexandra; Haney, Anessa; Boehm, Ulrich; Kharas, Michael G; Lengner, Christopher J; MacNicol, Melanie C; MacNicol, Angus M; Childs, Gwen V; Odle, Angela Katherine; Habra, Mouhammed Amir; Hammer, Gary D; Kebebew, Electron; Worden, Francis P; Raj, Nitya; Hallanger-Johnson, Julie E; Grauer, Andreas; Moraitis, Andreas
Checkpoint
肿瘤
肿瘤免疫
信号转导
免疫/内分泌
